Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8482-8490

  Ye, Ying ^a   McDevitt, Michael A ^a   Guo, Mingzhou ^a   Zhang, Wei ^a   Galm, Oliver ^c   Gore, Steven D ^a   Karp, Judith E ^a   Maciejewski, Jaroslaw P ^d   Kowalski, Jeanne ^b   Tsai, Hua Ling ^b   Gondek, Lukasz P ^d   Tsai, Hsing Chen ^a   Wang, Xiaofei ^a   Hooker, Craig ^a   Smith, B Douglas ^a   Carraway, Hetty E ^a   Herman, James G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; CATENIN ALPHA 1; HISTONE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; CHROMATIN; CHROMOSOME 5Q; CHROMOSOME DELETION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; TUMOR SUPPRESSOR GENE;

ALPHA CATENIN; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMES, HUMAN, PAIR 5; DNA METHYLATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUCIFERASES; LYMPHOCYTES; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70350539558     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1153     Document Type: Article

References (48)

1. Brunning RD. MDS - new classification, new problem? Leuk Res 2003;27:567-569
2. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98:2935-2941
3. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253-3260
4. Nimer SD, Golde DW. The 5q-abnormality. Blood 1987;70:1705-1712
5. Giagounidis AAN, Germing U, Haase S. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2003;18: 113-119 (Pubitemid 38159446)
6. Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008;140:267-278
7. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006;24:2576-2582 (Pubitemid 46630637)
8. Boultwood J, Fidler C, Strickson AJ. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002;99:4638-4641 (Pubitemid 34627240)
9. Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L. Physical mapping of the minimal region of loss in 5q-chromosome. Proc Natl Acad Sci U S A 1995;92:7406-7410
10. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 1996;88:2665-2670 (Pubitemid 26327519)
11. Zhao N, Stoffel A, Wang PW. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997;94:6948-6953 (Pubitemid 27281971)
12. Joslin JM, Fernald AA, Tennant TR. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110:719-726
13. Ebert BL, Pretz J, Bosco J. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008;451:335-339
14. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002;20:167-176 (Pubitemid 36070076)
15. Rush LJ, Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett 2002;185:1-12. (Pubitemid 34876527)
16. Horrigan SK, Arbieva ZH, Xie HY. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000;95:2372-2377
17. Liu TX, Becker MW, Jelinek J. Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007;13:78-83. (Pubitemid 46067389)
18. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 2007;21:1026-1034 (Pubitemid 46672080)
19. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826
20. Zhang W, Glockner SC, Guo M. Epigenetic inactivation of the canonical Wnt antagonist SRY-Box containing gene 17 in colorectal cancer. Cancer Res 2008;68: 2764-2772 (Pubitemid 351556274)
21. Boultwood J, Fidler C, Lewis S. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. Blood 1993;82:2611-2616 (Pubitemid 23318066)
22. Zavadil J, Brezinová J, Svoboda P, Zemanová Z, Michalová K. Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60. Leukemia 1997;11:1187-1192 (Pubitemid 27387290)
23. Hejlik DP, Kottickal LV, Liang H. Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor. Cancer Res 1997;57:3779-3783 (Pubitemid 27381223)
24. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006;91:1147-1148 (Pubitemid 44204790)
25. Valk PJM, Verhaak RGW, Beijen MA. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-1628 (Pubitemid 38528701)
26. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-Cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 2000;6:4243-4248
27. Cameron EE, Baylin SB, Herman JG. p15INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999;94:2445-2451
28. Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57: 837-841
29. Quesnel B, Guillerm G, Vereecque R. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990 (Pubitemid 28227550)
30. Mendes-da-Silva P, Moreira A, Duro-da-Costa J, Matias D, Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol Pathol 2000;53:184-187 (Pubitemid 30603072)
31. Ogasawara S, Tamura G, Maesawa C. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 1996;110:52-57 (Pubitemid 26021604)
32. Tamura G, Ogasawara S, Nishizuka S. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996;56:612-615 (Pubitemid 26043662)
33. Kadowaki T, Shiozaki H, Inoue M. E-Cadherin and {α}-catenin expression in human esophageal cancer. Cancer Res 1994;54:291-296 (Pubitemid 2019279)
34. Setoyama T, Natsugoe S, Okumura H. α-Catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J Surg Oncol 2007;95: 148-155 (Pubitemid 46238984)
35. Zhou YN, Xu CP, Chen Y, Han B, Yang SM, Fang DC. α-Catenin expression is decreased in patients with gastric carcinoma. World J Gastroenterol 2005;11:3468-3472 (Pubitemid 40873257)
36. Furley AJ, Reeves BR, Mizutani S. Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. Blood 1986;68:1101-1107 (Pubitemid 17186387)
37. Dodge JE, Munson C, List AF. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 2001;25:917-925 (Pubitemid 32776583)
38. Mrózek K, Tanner SM, Heinonen K, Bloomfield CD. Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence insitu hybridization. Genes Chromosomes Cancer 2003;38:249-252 (Pubitemid 37259642)
39. Soengas MS, Capodieci P, Polsky D. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211 (Pubitemid 32144287)
40. Azuara V, Perry P, Sauer S. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 2006;8:532-538
41. Bernstein BE, Mikkelsen TS, Xie X. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-326
42. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006;66:3541-3549
43. Schoch C, Kohlmann A, Dugas M. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia 2005;19:1224-1228
44. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23-32.
45. Galm O, WilopS, Lüders C. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 2005;84:39-46. (Pubitemid 44419738)
46. Vire E, Brenner C, Deplus R. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-874 (Pubitemid 43255707)
47. Lee TI, Jenner RG, Boyer LA. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 2006;125:301-313 (Pubitemid 44313811)
48. Ohm JE, McGarvey KM, Yu X. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-242 (Pubitemid 46184356)